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Abstract: SERCA2a is the Ca2+ ATPase playing the major contribution in cardiomyocyte (CM) calcium
removal. Its activity can be regulated by both modulatory proteins and several post-translational
modifications. The aim of the present work was to investigate whether the function of SERCA2 can
be modulated by treating CMs with the histone deacetylase (HDAC) inhibitor suberanilohydroxamic
acid (SAHA). The incubation with SAHA (2.5 µM, 90 min) of CMs isolated from rat adult hearts
resulted in an increase of SERCA2 acetylation level and improved ATPase activity. This was associated
with a significant improvement of calcium transient recovery time and cell contractility. Previous
reports have identified K464 as an acetylation site in human SERCA2. Mutants were generated
where K464 was substituted with glutamine (Q) or arginine (R), mimicking constitutive acetylation or
deacetylation, respectively. The K464Q mutation ameliorated ATPase activity and calcium transient
recovery time, thus indicating that constitutive K464 acetylation has a positive impact on human
SERCA2a (hSERCA2a) function. In conclusion, SAHA induced deacetylation inhibition had a
positive impact on CM calcium handling, that, at least in part, was due to improved SERCA2 activity.
This observation can provide the basis for the development of novel pharmacological approaches to
ameliorate SERCA2 efficiency.
Keywords: SERCA2; acetylation; HDAC inhibition; ATPase activity; calcium transients;
cardiomyocyte mechanics
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1. Introduction
The Sarco(Endo)plasmic Reticulum (SR) Ca2+ ATPase (SERCA) is a Ca2+ pump that uses the
energy of ATP hydrolysis to translocate two Ca2+ ions from the cytosol to the SR lumen. It is composed
of a single polypeptide weighing approximately 110 kDa and organized into four different domains:
one transmembrane domain composed of ten alpha-helices, one nucleotide (ATP) binding site, one
phosphorylation/catalytic domain that drives ATP hydrolysis, and one actuator domain involved in
the gating mechanism that regulates calcium binding and release [1,2]. In vertebrates, three different
SERCA genes have been identified so far, showing high degree of conservation among species: ATP2A1,
ATP2A2 and ATP2A3, encoding respectively for the SERCA1, SERCA2 and SERCA3 proteins. Thanks
to alternative splicing mechanisms, they can give rise to different protein isoforms, whose expression
is regulated during development and in a tissue specific manner [3]. SERCA2a is the most expressed
isoform in cardiac muscle [3] and is the responsible for the level of SR Ca2+ load and the majority
of the cytosolic calcium removal after contraction (70% in human, up to 90% in mouse and rats),
thus representing a key player for cardiomyocyte (CM) relaxation [4]. Alterations in SERCA2a are
recognized among the major factors contributing to ventricular dysfunction in several heart diseases,
like diabetic cardiomyopathy [5,6] and heart failure [7,8].
Owing its essential role in cardiac physiology, the mechanisms regulating SERCA2a have
been extensively studied [9]. Evidence has been provided that the pump activity can be directly
modulated by several post-translational modifications [10]. Specifically, sumoylation [11] and
glutathionylation [12] increase the activity, while glycosylation [13] and nitration [14] seem to decrease
SERCA2a function. A recent study by Foster and coworkers [15] identified three acetylation sites within
the structure of SERCA2a. However, the potential impact of SERCA2a acetylation on intracellular Ca2+
cycling has never been evaluated.
The enzymes responsible for protein acetylation and deacetylation are histone acetyltransferases
(HATs) and histone deacetylases (HDACs), respectively. HATs and HDACs act not only on histones,
but also on other nuclear and cytoplasmic proteins, such as transcription factors and structural
proteins [16].
The acetylation balance carried out by HATs and HDACs plays a role in the physiology of adult
CMs. For instance, it has been demonstrated that HDAC inhibition prevented ventricular arrhythmias
and restored conduction defects of the heart in a model of dystrophic mice [17].
The specific aim of the present work was to investigate the impact of deacetylation inhibition on
SERCA2 activity. Specifically, adult ventricular CMs isolated from normal rat hearts were exposed
to the HDAC general inhibitor suberanilohydroxamic acid (SAHA, or Vorinostat). Additionally,
three stable lines of HEK cells were produced to express the human SERCA2a either wild type or with
mutations mimicking constitutive acetylation/deacetylation on a selected lysine residue.
In this manuscript, we demonstrate for the first time that HDAC inhibition promotes improved
efficiency in cytosolic Ca2+ removal, along with increased SERCA2 acetylation and ATPase activity.
2. Results
2.1. Effect of SAHA Treatment on SERCA2a Acetylation and Function in Control Rat Cardiomyocytes
Cardiomyocytes (CMs) isolated from normal adult rat hearts were used as model to investigate
whether SAHA-promoted HDAC inhibition can impact SERCA2a acetylation and function. Following
enzymatic dissociation, CMs were either untreated (CTR) or incubated with 2.5 µM SAHA
(CTR+SAHA) for 90 min. As expected [18], SAHA administration induced higher tubulin acetylation
level (Figure 1a).
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Figure 1. Effect of SAHA treatment on cardiomyocytes isolated from adult rat hearts. (a) Western blot 
panels (on the left) and densitometric analysis (on the right) showing SERCA2 and Ac-Tubulin 
protein expression after SAHA treatment (n = 7). Mann–Whitney U-test: * p < 0.005 vs. CTR; (b) 
Immunoprecipitation experiments and densitometric analysis (on the right) indicating higher 
acetylation level of SERCA2 after SAHA treatment (n = 5). Mann–Whitney U-test: * p < 0.005 vs. CTR;  
(c) Western blot analysis showing the expression of phosphorylated phospholamban (Phospho-PLB, 
Ser16) compared to total phospholamban (PLB) in adult rat CMs after SAHA treatment (n = 7). 
Co-immunoprecipitation experiments revealed that SAHA increased SERCA2 acetylation level 
(Figures 1b and S1), without inducing significant changes in SERCA2 protein expression (Figure 1a). 
The ratio of phosphorylated phospholamban (PLB)/total phospholamban (Figure 1c) remained 
unchanged. 
To investigate whether increased acetylation could also affect SERCA2 functional properties, 
ATPase activity was measured on microsomes [19] isolated from both CTR and CTR+SAHA CMs. 
HDAC inhibition resulted in an increase of ATPase activity when microsomes were exposed to 10 
µM calcium concentration (corresponding to pCa5) [20,21] (Figure 2a). 
Figure 1. Effect of SAHA treatment on cardiomyocytes isolated from adult rat hearts. (a) Western
blot panels (on the left) and densitometric analysis (on the right) showing SERCA2 and Ac-Tubulin
protein expression after SAHA treatment (n = 7). Mann–Whitney U-test: * p < 0.005 vs. CTR;
(b) Immunoprecipitation experiments and densitometric analysis (on the right) indicating higher
acetylation level of SERCA2 after SAHA treatment (n = 5). Mann–Whitney U-test: * p < 0.005 vs. CTR;
(c) Western blot analysis showing the expression of phosphorylated phospholamban (Phospho-PLB,
Ser16) compared to total phospholamban (PLB) in adult rat CMs after SAHA treatment (n = 7).
Co-immunoprecipitation experiments revealed that SAHA increased SERCA2 acetylation level
(Figure 1b and Figure S1), without inducing significant changes in SERCA2 protein expression
(Figure 1a). The ratio of phosphorylated phospholamban (PLB)/total phospholamban (Figure 1c)
remained unchanged.
To investigate whether increased acetylation could also affect SERCA2 functional properties,
ATPase activity was measured on microsomes [19] isolated from both CTR and CTR+SAHA CMs.
HDAC inhibition resulted in an increase of ATPase activity when microsomes were exposed to 10 µM
calcium concentration (corresponding to pCa5) [20,21] (Figure 2a).
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Figure 2. Effect of SAHA treatment on SERCA2 ATPase activity evaluated in cardiomyocytes isolated 
from adult rat hearts and HL-1 cells. (a) ATPase activity assay performed on microsomes isolated 
from adult rat CMs either untreated or treated with SAHA at pCa5. Experiments were performed on 
3 independent CM sets per group and repeated twice. Unpaired Student’s t-test: * p < 0.005 vs. CTR; 
(b) ATPase activity assay performed on microsomes isolated from HL-1 cells at different pCa. Each 
point represents the mean ± SEM of at least 4 independent experiments; Two-way ANOVA followed 
by Sidak’s multiple comparison: * p < 0.05 vs. SAHA pCa6; # p < 0.05 vs. SAHA pCa5. All data are 
presented as mean ± SEM. 
In order to confirm our result on SERCA2 functional properties, we decided to perform an 
additional set of experiments measuring ATPase activity on microsomes isolated from HL-1 cells, 
derived from the AT-1 mouse atrial cardiomyocyte tumor lineage. These cells partially maintain an 
adult cardiac phenotype and are able to contract [22]. The calcium-dependence of ATPase activity on 
HL-1 cells, either untreated (CTR) or treated for 90 min with 2.5 µM SAHA, was analyzed at different 
calcium concentration (from pCa8 to pCa5). ATPase activity of microsomes extracted from HL-1 cells 
was increased after SAHA treatment in comparison with CTR and the difference reached statistical 
significance when microsomes were exposed to 1 and 10 µM calcium concentration (corresponding 
to pCa6 and pCa5, respectively; Figure 2b). 
2.2. Effect of SAHA Treatment on Calcium Transients and Cell Mechanics in CMs Isolated from Adult Rat 
Hearts 
We then investigated whether SAHA treatment affected CM functional parameters that directly 
depend on SERCA2 activity, namely calcium transients and cell contractility. The amplitude and the 
time to peak (TTP) of the calcium transient were comparable in CTR and CTR+SAHA groups, while 
the rate of cytosolic calcium clearing was significantly higher in SAHA-treated cardiomyocytes 
(Figure 3a,c). Specifically, SAHA induced a 21% decrease in the time constant tau, as well as a 
significant reduction in the time to 10%, 50% and 90% of fluorescence signal decay (BL10, BL50, BL90; 
Figure 3c). Consistent with this finding, SAHA also affected CM mechanics during the re-lengthening 
phase, as documented by the significant increase in the maximal rate of re-lengthening (+dl/dtmax, 
approximately 16%) associated with a decrease in the time to 10%, 50% and 90% of re-lengthening 
(Figure 3b,d). Conversely, the average diastolic sarcomere length, the fraction of shortening and the 
maximal rate of shortening were comparable in CTR and CTR+SAHA cardiomyocytes (Figure 3d). 
Of note, SAHA exposure, at the conditions used in the present manuscript (90 min, 2.5 µM), did not 
affect cardiomyocytes diastolic nor systolic calcium concentration assessed by Fura-2 dye (Figure S2). 
Figure 2. Effect of SAHA treatment on SERCA2 ATPase activity evaluated in cardiomyocytes isolated
from adult rat hearts and HL-1 cells. (a) ATPase activity assay performed on microsomes isolated
from adult rat CMs either untreated or treated with SAHA at pCa5. Experiments were performed
on 3 independent CM sets per group and repeated twice. Unpaired Student’s t-test: * p < 0.005 vs.
CTR; (b) ATPase activity assay performed on microsomes isolated from HL-1 cells at different pCa.
Each point represents the mean ± SEM of at least 4 independent experiments; Two-way ANOVA
followed by Sidak’s multiple comparison: * p < 0.05 vs. SAHA pCa6; # p < 0.05 vs. SAHA pCa5.
All data are presented as mean ± SEM.
In order to confirm our result on SERCA2 functional properties, we decided to perform an
additional set of experiments measuring ATPase activity on microsomes isolated from HL-1 cells,
derived from the AT-1 mouse atrial cardiomyocyte tumor lineage. These cells partially maintain an
adult cardiac phenotype and are able to contract [22]. The calcium-dependence of ATPase activity on
HL-1 cells, either untreated (CTR) or treated for 90 min with 2.5 µM SAHA, was analyzed at different
calcium concentration (from pCa8 to pCa5). ATPase activity of microsomes extracted from HL-1 cells
was increased after SAHA treatment in comparison with CTR and the difference reached statistical
significance when microsomes were exposed to 1 and 10 µM calcium concentration (corresponding to
pCa6 and pCa5, respectively; Figure 2b).
2.2. Effect of SAHA Treatment on Calcium Transients and Cell Mechanics in CMs Isolated from Adult
Rat Hearts
We then investigated whether SAHA treatment affected CM functional parameters that directly
depend on SERCA2 activity, namely calcium transients and cell contractility. The amplitude and
the time to peak (TTP) of the calcium transient were comparable in CTR and CTR+SAHA groups,
while the rate of cytosolic calcium clearing was significantly higher in SAHA-treated cardiomyocytes
(Figure 3a,c). Specifically, SAHA induced a 21% decrease in the time constant tau, as well as a
significant reduction in the time to 10%, 50% and 90% of fluorescence signal decay (BL10, BL50, BL90;
Figure 3c). Consistent with this finding, SAHA also affected CM mechanics during the re-lengthening
phase, as documented by the significant increase in the maximal rate of re-lengthening (+dl/dtmax,
approximately 16%) associated with a decrease in the time to 10%, 50% and 90% of re-lengthening
(Figure 3b,d). Conversely, the average diastolic sarcomere length, the fraction of shortening and the
maximal rate of shortening were comparable in CTR and CTR+SAHA cardiomyocytes (Figure 3d).
Of note, SAHA exposure, at the conditions used in the present manuscript (90 min, 2.5 µM), did not
affect cardiomyocytes diastolic nor systolic calcium concentration assessed by Fura-2 dye (Figure S2).
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Figure 3. Effect of SAHA treatment on calcium transients and cell mechanics in CMs isolated from 
adult rat hearts. Representative examples of calcium transients (a) normalized traces: fold increase 
and sarcomere shortening (b) recorded from CTR (black line) and CTR+SAHA (red line) ventricular 
myocytes. (c) Calcium transient parameters: amplitude of calcium transient (expressed as calcium 
peak fluorescence normalized to baseline fluorescence, f/f0: fold increase), time to peak of the calcium 
transient (TTP), time constant of the rate of intracellular Ca2+ clearing (tau), and recovery phase of 
Ca2+ transients indicated as time to 10% (BL10), 50% (BL50) and 90% (BL90) of fluorescence signal 
decay. (d) Cell mechanics: diastolic sarcomere length and fraction of shortening (FS), maximal rates 
of shortening (−dl/dtmax) and re-lengthening (+dl/dtmax), time of re-lengthening at 10% (RL10), 50% 
(RL50) and 90% (RL90). All data are presented as mean ± SEM and analysed using General Linear 
Model (GLM) ANOVA for repeated measurements (n = 45 untreated CMs, n = 70 CMs treated with 
SAHA): * p < 0.005 vs. CTR. 
2.3. Nε-Lysine Acetylation Sites of Human SERCA2a 
To support the hypothesis that direct acetylation can boost SERCA2a function, we searched in 
PHOSIDA and PhosphoSitePlus for reported Nε-lysine acetylation sites in human SERCA2. 
PHOSIDA Post Translation Modification Database reports acetylation at K464, while 
PhosphoSitePlus reports acetylation at K31, K33, K218, K464, K476 and K514. All these residues are 
mostly conserved in mammals (Figure S3). Out of these candidates, site K464 was selected as the 
Figure 3. Effect of SAHA treatment on calcium transients and cell mechanics in CMs isolated from
adult rat hearts. Representative examples of calcium transients (a) normalized traces: fold increase
and sarcomere shortening (b) recorded from CTR (black line) and CTR+SAHA (red line) ventricular
myocytes. (c) Calcium transient parameters: amplitude of calcium transient (expressed as calcium
peak fluorescence normalized to baseline fluorescence, f/f0: fold increase), time to peak of the calcium
transient (TTP), time constant of the rate of intracellular Ca2+ clearing (tau), and recovery phase of
Ca2+ transients indicated as time to 10% (BL10), 50% (BL50) and 90% (BL90) of fluorescence signal
decay. (d) Cell mechanics: diastolic sarcomere length and fraction of shortening (FS), maximal rates of
shortening (−dl/dtmax) and re-lengthening (+dl/dtmax), time of re-lengthening at 10% (RL10), 50%
(RL50) and 90% (RL90). All data are presented as mean ± SEM and analysed using General Linear
Model (GLM) ANOVA for repeated measurements (n = 45 untreated CMs, n = 70 CMs treated with
SAHA): * p < 0.005 vs. CTR.
2.3. Nε-Lysine Acetylation Sites of Human SERCA2a
To support the hypothesis that direct acetylation can boost SERCA2a function, we searched in
PHOSIDA and PhosphoSitePlus for reported Nε-lysine acetylation sites in human SERCA2. PHOSIDA
Post Translation Modification Database reports acetylation at K464, while PhosphoSitePlus reports
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acetylation at K31, K33, K218, K464, K476 and K514. All these residues are mostly conserved in
mammals (Figure S3). Out of these candidates, site K464 was selected as the target for further
analysis given two previous independent reports identifying K464 as an acetylation site in human
SERCA2 [23,24]. Homology modeling results indicate that K464 is solvent accessible at the surface of
the nucleotide binding-domain (Figure 4a and Figure S4).
To assess the impact of Nε-lysine acetylation on hSERCA2a function, two different mutants were
generated where lysine in position 464 was changed into glutamine (Q) or arginine (R) to mimic
constitutive acetylation or constitutive deacetylation, respectively [15]. The expression of either the
hSERCA2a wild type form (WT) and the mutant forms (K464Q/R) was induced in HEK human cells
(Figure 4b), expressing lower levels of the SERCA2 isoform compared to other commonly used human
cell lines, such as HeLa. SERCA2 expression was significantly increased in all stable transfected HEK
cells compared to non-transfected cells (NT; Figure 4b). However, although the observed difference did
not reach statistical significance, the expression of SERCA2 appeared lower in both mutants compared
to the HEK transfected with WT (Figure 4b).
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2.4. Effects of K464 Mutation on hSERCA2a ATPase Activity and HEK Calcium Transients 
The effects of mutagenesis were evaluated on ATPase activity measured in the microsomal 
fraction isolated from transfected HEK cells. In order to take into consideration the possible impact 
of different level of protein expression on hSERCA2a function, the values of ATPase activity recorded 
for each sample were normalized to the correspondent SERCA2 expression evaluated by Western 
blot on cells obtained from the same sample (Figure 4b). Taking into account the variable amount of 
SERCA2 expression in each cell line and for each experiment, we observed that SERCA2 function was 
significantly ameliorated in mutants where K464 were mutated into Q compared with WT (Figure 
Figure 4. Analysis of human SERCA2a mutants transfected in HEK cells: bioinformatics prediction
and protein expression. (a) Molecular surface view of predicted hSERCA2a. Domains are visualized in
different colors: Actuator (A) in light blue, transmembrane (M) in dark blue, phosphorylation (P) in
yellow and nucleotide-binding (N) in beige. K464 is highlighted in red; (b) Western blot analysis of
SERCA2 expression in stable transfected HEK cells. Densitometry is reported in the bar graph (n = 8).
Ordinary one-way ANOVA followed by Bonferroni’s multiple comparison: p < 0.005 vs. NT.
2.4. Effects of K464 Mutation on hSERCA2a ATPase Activity and HEK Calcium Transients
The effe ts of mutagenesis wer ev luated ATPase activity measured in the microsomal
fraction isolate from transfected HEK c lls. In order to take into consideration the possible impa t of
different level of protein expression on hSERCA2a function, the values of ATPase activity record
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for each sample were normalized to the correspondent SERCA2 expression evaluated by Western
blot on cells obtained from the same sample (Figure 4b). Taking into account the variable amount of
SERCA2 expression in each cell line and for each experiment, we observed that SERCA2 function was
significantly ameliorated in mutants where K464 were mutated into Q compared with WT (Figure 5a).
Conversely, the K464R mutant did not show any differences in comparison with the WT (Figure 5a).
Thus, constitutive acetylation of hSERCA2a K464 improved hSERCA2a ATPase activity, while K464
mutation into R (constitutive deacetylation) did not have a significant effect (Figure 5a). Importantly,
untransfected HEK cells responded with a transient increase of intracellular calcium concentration
to caffeine puff (1 s, 10 mM, Figure 5b). Therefore, we further evaluated the effects of SERCA2a
mutagenesis on calcium transients induced by caffeine in HEK cells loaded with the calcium sensitive
dye Fluo-4. Again, in order to consider the effects of different SERCA2 protein levels in HEK mutants,
calcium transients were corrected on the mean SERCA2 expression detected by Western Blot in the
correspondent cell line. The constitutive acetylation of SERCA2 K646Q promoted an acceleration of
Ca2+ transient recovery phase at BL10%, BL50% compared to WT and K464R (Figure 5c), thus indicating
that constitutive acetylation of K464 has a positive impact on hSERCA2a function.
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3. Discussion 
SERCA2 activity has been recently suggested to be affected by acetylation/deacetylation 
mechanisms [11,15], although no experimental evidence has so far been provided. In the present 
work, we show that HDAC inhibition promotes SERCA2 acetylation. This is associated with a 
significant increase of microsomal ATPase activity (which is recognized to be mainly due to SERCA2 
Figure 5. ATPase activity on microsomes and calcium transients evaluated in HEK cells transfected
with human SERCA2a mutants. (a) ATPase activity assay performed on microsomes isolated from
stable transfected HEK cells at pCa5 normalized on SERCA2 protein expre sion. Experiments were
performed on 4 independent HEK sets per group and repeated twice. Ordinary one-way ANOVA
followed by Bonferr i’s lti l comparison: p < 0. 5 WT vs. K46 Q. All data re pr sented as mean
± SEM; (b) Representative trace of the rise in intracellular calcium concentratio evoked by a caffeine
pulse in ntransfected HEK cells; (c) Calcium transients in SERCA2a K464 mutants normalized on
SERCA2 protein expression. K464 is mutated either into Q or R, mimicking constitutive acetylation and
deacetylation, respectively (n = 99 WT, n = 69 K464Q and n = 36 K464R). Time to 10% (BL10) and time to
90% (BL90) were analysed by Kruskal-Wallis followed by Dunn’s multiple comparisons test: * p < 0.005
WT vs. K464Q, # p < 0.005 K464Q vs. K464R. Time to 50% (BL50) was analysed by ordinary one-way
ANOVA followed by Bonferroni’s multiple comparisons test: * p < 0.005 WT vs. K464Q, # p < 0.005
K464Q vs. K464R. All data are presented as mean ± SEM.
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3. Discussion
SERCA2 activity has been recently suggested to be affected by acetylation/deacetylation
mechanisms [11,15], although no experimental evidence has so far been provided. In the present work,
we show that HDAC inhibition promotes SERCA2 acetylation. This is associated with a significant
increase of microsomal ATPase activity (which is recognized to be mainly due to SERCA2 function [25])
and a significant amelioration of calcium clearing parameters measured in CMs isolated from normal
adult rats. Our results indicate for the first time a relation between HDACs, SERCA2 acetylation and
its function. In addition, lysine 464 has been mutated in the human SERCA2a (hSERCA2a) coding
sequence transfected in a HEK stable expression system, in order to provide evidence for a causal
association between SERCA2 deacetylation and the ATPase activity of the pump.
In our CM experimental model, SERCA2 acetylation was promoted by SAHA (Vorinostat),
a general HDAC inhibitor, acting on class I and II HDACs [26]. SAHA use was approved by the
US FDA in October 2006 for the treatment of refractory cutaneous T-cell lymphoma [27]. Although
several in vitro studies [28,29] have reported that 2.5 µM SAHA is able to inhibit the growth of
cancer cells, it has also been reported that 2 µM SAHA is able to reduce CM death after simulated
ischaemia/reperfusion injury [30]. In our work, the decision to treat adult CMs with 2.5 µM SAHA
for 90 min was taken on the basis of current literature showing that SAHA in the range of 1 to 5 µM
increases histone acetylation in an in vitro model within one hour, reaching the plateau effect at
3 h [31]. Therefore, we assumed that 90 min are sufficient to achieve the acetylation increase of all
the other HDAC potential targets, including cytoplasmic substrates and to preserve cell viability.
We demonstrated higher levels of SERCA2 acetylation following SAHA treatment in adult CMs from
CTR rats by immunoprecipitation and Western blot for Acetylated-Lysine. The SERCA2 ATPase
activity has been then explored using isolated microsomes from normal adult rat CMs, where an
increase has been shown after SAHA treatment. Although it is a common praxis to perform measures
at pCa5 [21,32–34], we decided to test the calcium-dependence of ATPase activity in order to confirm
our results on SERCA2 ATPase activity also using microsomes isolated from HL-1 cells, as additional
in vitro model. Specifically, HL-1 cells, derived from mouse atrial cardiomyocyte tumor lineage [22],
represent a more abundant source of cardiomyocytes compared to freshly isolated rat adult CMs.
The treatment with SAHA ameliorated intracellular Ca2+ dynamics and, accordingly, contractile
performance of adult rat CMs. These findings support the hypothesis that the inhibition of SERCA2
deacetylation induced by SAHA plays a crucial role in promoting a more efficient SR calcium re-uptake,
which in turn results in a higher rate of re-lengthening and shorter relaxation times [35].
In view of these results, one should also consider that Gupta and colleagues recently observed
an enhanced calcium sensitivity of myofilaments following HDAC inhibition. This aspect can play
a key role in explaining the improved contractile efficiency of SAHA treated CMs [36]. On the other
hand, an increase of myofilament calcium sensitivity would be expected to delay SR Ca2+ uptake and
consequently prolong twitch duration, thus having an opposite effect compared to our observation.
Nevertheless, it is important to notice that Gupta and coworkers have demonstrated that acetylation
increases myofilament Ca2+ sensitivity in a model of skinned cardiac papillary muscle fibers [36]. It is
known that the muscle skinning process leads to the loss of all the other sensitizing and desensitizing
intracellular components that synergistically act in determining the effective calcium sensitivity of
myofilaments [37]. Therefore it is conceivable that the discrepancy between our and Gupta results
depends, at least in part, on the use of a whole cell model instead of a reductionist model consisting
only of free calcium ions and myofilaments.
It is now well recognized that Ca2+ handling not only governs contractile events, but can also
directly or indirectly influence ion channel function in cardiomyocytes, resulting in electrophysiological
effects. An important component of Na+ channel regulation is due to Ca2+, calmodulin (CaM) and
CaM-dependent protein kinase II (CaMKII) pathway that affects channel function [38]. L-type Ca2+
(ICaL) and sodium(Na+)-Ca2+ exchanger (NCX) currents are Ca2+-sensitive, as well as the slowly
activating delayed rectifier current (IKs), which plays an important role in regulating action potential
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duration [39,40]. In this work, we did not perform electrophysiological measurements on isolated
ventricular myocytes that could help us in evaluating the impact on cardiac ion channels and pumps of
SERCA2a activity amelioration induced by SAHA deacetylation inhibition. However, several findings
reported in the present study can be useful to speculate on this topic. We observed that the amplitude
of the calcium transient, which is dependent on the amplitude of Ca2+ entry, was comparable in control
and SAHA-treated cardiomyocytes, suggesting that SAHA does not induce substantial changes in
the calcium entry, through L-type Ca2+ channels and reverse activity of NCX. In addition, ryanodine
receptors should not be affected by SAHA treatment, as indirectly suggested by the calcium transient
rate of rise, measured as time to peak fluorescence, showing similar values in treated and untreated
cells. Also, it should be considered that diastolic and systolic cytosolic Ca2+ levels were unchanged
in SAHA treated cells as compared to control cardiomyocytes. This observation, besides confirming
that calcium homeostasis is maintained even in the presence of a faster SERCA2 calcium re-uptake,
should imply no changes in both the intracellular Na+ concentration that is tightly coupled to calcium
concentration regulation, via electrogenic Na+/Ca2+ exchange, and Ca2+-sensitive IKs current.
Interestingly, it has been recently shown that SAHA administration in vivo in a mouse model of
muscular dystrophy can reduce the appearance of cardiac arrhythmias by reverting the remodeling
of connexins and sodium channels [17]. Although the mechanisms of action are still unclear, those
findings, together with our results, support the positive effect of SAHA treatment on cardiac function.
In order to explore possible acetylation sites influencing human SERCA2 activity, 3D models of
hSERCA2a were produced by bioinformatic prediction methods, identifying the residue 464 as the
most promising candidate. Residue K464 is located at the surface of the N domain in hSERCA2a.
Although homology modeling of the different conformational states does not reveal an obvious
functional impact for the K464 acetylation, the site is expected to locate on the side of a large cleft in
state E2P [1,41] at the interface between domains N, P and M, near a putative phospholamban binding
site (Figure S4). The potential effect of the K464 acetylation in protein electrostatics, flexibility and
phospholamban binding affinity should be further investigated. Indeed, this lysine, conserved in all
mammals, has already been reported as acetylated in the guinea pig heart, although no evidence of its
functional role has been provided [15].
We produced three mutant HEK lines expressing WT hSERCA2a, or hSERCA2a where K464
was mutated into Q or R, mimicking constitutive acetylated and deacetylated state of the residue,
respectively [15]. Of note, HEK cells have already been used by other groups as a valuable model to
overexpress mutant SERCA and to study the consequent effects on the protein pumping activity [11].
HEK cells overexpressing mutated SERCA have also been recently used as a tool to investigate
intracellular calcium dynamics [42]. Importantly, despite the debate on the presence of functional
RyRs in HEK cells [43–45], we found that the application of a pulse of caffeine caused the abrupt
increase of intracellular calcium concentration. Therefore, we decided to expose HEK cells transfected
with WT hSERCA2a or mutated hSERCA2a to caffeine in order to increase the intracellular calcium
concentration and then compare the time of recovery in WT compared to mutants. It is important to
notice that, although the recovery phase in HEK cells was considerably longer than that observed
in adult cardiomyocytes, SERCA has been described as the major player in the recovery of calcium
transients long up to 4 s [46]. We cannot exclude a possible involvement of other Ca2+ removal systems
(such as mitochondria and Peripheral Membrane Calcium ATPase) as well as of Ca2+ buffering in
restoring basal conditions. However, given that in our experimental conditions the hSERCA2a pump
was overexpressed, we can reasonably assume that the recovery phase in (transfected) HEK cells
at least partially depends on the activity of transfected hSERCA2a. Intriguingly, K464Q mutants
exhibited a higher ATPase activity and an acceleration of Ca2+ transient recovery phase compared
to WT, supporting the hypothesis that the acetylation is a positive regulator of SERCA2 function.
However, it is important to notice that SAHA could inhibit the acetylation of different lysine residues
at the same time. Thus, mutating only one lysine at a time might only partially mimic the global effect
obtained after HDAC inhibition on CMs.
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Interestingly, Hajjar and coworkers demonstrated that sumoylation of lysine residue 585 enhances
SERCA2a stability and activity [11]. It has been recently shown that HDAC inhibition can stimulate
protein sumoylation possibly through acetylation of the SUMO machinery [47]. Thus, our findings in
isolated SAHA-treated cardiomyocytes sustain the idea that HDAC-inhibition could support other
approaches, such as SUMO-1 overexpression [11], in the treatment of heart disease associated with
SERCA2 impairment.
The main limitation of the present study is the fact that acetylation is only one of the factors
contributing to SERCA2 function in health and disease. Additionally, we cannot exclude a possible
action of SAHA on other proteins, such as SERCA2 interacting proteins or transporters involved
in calcium dynamics, such as the sodium-calcium exchanger [48]. However, SERCA2 is recognized
as the main player in calcium re-uptake during the relaxation/recovery phase in CMs, removing
approximately 70–90% of calcium ions from the cytosol in species including humans, mice and rats [4].
This observation let us hypothesize that SERCA2 is the key factor in SR reuptake whose function is
modulated by SAHA. The fact that the time to peak (TTP) of calcium transients recorded in isolated
rat cardiomyocytes remained unchanged following SAHA administration seems also to indicate that
RyRs are not affected by the treatment, at least under our experimental conditions. Further, our results
indicate that phosphorylated and total PLB remain unchanged after treatment, thus suggesting that
PKA activity might not be affected by SAHA. Nevertheless, deeper investigation are required in
order to explain whether acetylation can directly or indirectly modulate other mechanisms of SERCA2
regulation, like CAMKII mediated phosphorylation. Importantly, it has been recently hypothesized
that SERCA2 can be potentially regulated by microRNAs [49]. Concomitantly, experimental evidence
has been provided that knock-out mice for miR-22 expression exhibit prolonged calcium transients and
a decrease of SERCA transcript induced by indirect interaction [50]. More recently, it has been shown
that miR-275 can directly target SERCA in mosquito gut [51], thus providing new basis for further
studies on SERCA regulation by microRNA in vertebrates and humans. In this context, it should
be reported that SAHA is well recognized as a microRNA modulator [52–54]. Further studies are
required to understand whether HDAC inhibition can exert its action on SERCA and calcium dynamics
by acting on microRNA target. Additionally, other potential mechanism of action should be taken
into consideration for future studies, such as the role of the TGF-beta pathway, already shown to be
involved in cardiac calcium signaling [55,56] and to be modulated by HDAC inhibitors in organs other
than heart [57–59].
However, we would like to underline the fact that the aim of the present paper was to evaluate
whether HDAC inhibition can modulate cardiac cell function by acting on SERCA2. SERCA2 is
reasonably one of the multiple targets of SAHA action that can result in the enhancement or in the
inhibition of many proteins, the net effect on EC coupling depending on the combination of the single
contributions and on the model used.
Another question remaining unanswered is which enzymes are responsible for SERCA2a
acetylation/deacetylation. It is known that SAHA at low concentration is a potent inhibitor of the
class I HDAC isoforms 1 and 8 (IC50 < 20 nM), while it is active on other class I and class II HDACs
at higher concentrations [60]. It is also well recognized that class II HDAC have both nuclear and
cytoplasmic localization [61]. However, although traditionally considered as nuclear enzymes, class I
HDACs have been recently demonstrated to be present in the endoplasmic reticulum [62]. Therefore,
it is conceivable that both class of enzymes might act on SERCA2, contributing to the control of its
acetylation status. Further studies are required to elucidate this point.
In conclusion, the results here demonstrate for the first time that SERCA2 acetylation and activity
are increased following HDAC inhibition promoted by SAHA. Importantly, our findings suggest that
the modulation of acetylation can be a novel strategy to treat diseases where calcium handling is
affected, such as diabetic cardiomyopathy [6,63], dilated cardiomyopathy [64], ischemia/reperfusion
injury [65], cardiac hypertrophy [66] and heart failure [67].
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4. Materials and Methods
4.1. Rat Population
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals (National Institute of Health, Bethesda, MD, USA, revised 1996).
The investigation was approved by the Veterinary Animal Care and Use Committee of the University
of Parma-Italy (Prot. No. 59/12; 9 May 2012) and conforms to the National Ethical Guidelines of the
Italian Ministry of Health. All efforts were made to minimize animal suffering.
The study population consisted of 5 male Wistar rats (Rattus norvegicus) aged 12–14 weeks,
weighing 379 ± 8 g, individually housed in a temperature-controlled room at 22–24 ◦C, with the light
on between 7.00 AM and 7.00 PM.
4.2. Rat Cardiomyocyte Isolation
Individual left ventricular (LV) cardiomyocytes (CMs) were enzymatically isolated by collagenase
perfusion from the adult rat hearts in accordance with a procedure previously described [68]. Briefly,
rats were anesthetised with ketamine chloride (Imalgene, Merial, Milan, Italy; 40 mg/kg ip) plus
medetomidine hydrochloride (Domitor, Pfizer Italia S.r.l., Latina, Italy; 0.15 mg/kg ip). The heart was
then removed and rapidly perfused at 37 ◦C by means of an aortic cannula with the following sequence
of solutions: (1) a calcium-free solution for 5 min to remove the blood. Calcium-free solution contains
the following (in mM): 126 NaCl, 22 dextrose, 5 MgCl2, 4.4 KCl, 20 taurine, 5 creatine, 5 sodium
pyruvate, 1 NaH2PO4, and 24 HEPES (pH 7.4, adjusted with NaOH), and the solution was gassed
with 100% O2; (2) a low-calcium solution (0.1 mM) plus 1 mg/mL type 2 collagenase (Worthington
Biochemical, NJ, USA) and 0.1 mg/mL type XIV protease (Sigma-Aldrich, Milan, Italy) for about
20 min; (3) an enzyme-free, low-calcium solution for 5 min. The left ventricle was then minced
and shaken for 10 min. The cells were filtered through a nylon mesh, re-suspended in low-calcium
solutions (0.1 mM) for 30 min, and then used for recording cell mechanics and calcium transients.
Following enzymatic dissociation, CMs were either untreated or incubated with 2.5 µM SAHA for
90 min. A fraction of cells from each experimental group was washed three times with low-calcium
solution and centrifuged (42× g for 5 min). After removing the supernatant, the pellet was stored at
−80 ◦C for subsequent microsome isolation (see the Section 4.6). The remaining cardiomyocytes were
used for recording cell mechanics and calcium transients, as described in the Section 4.8.
4.3. HL-1 Cardiomyocyte Culture
HL-1 cells, derived from the AT-1 mouse atrial cardiomyocyte tumor lineage [22], were kindly
donated by Prof. W.C. Claycomb. Cells were grown as previously described [22] in Claycomb Medium
(Sigma-Aldrich S.r.l., Milan, Italy) supplemented with 100 µM norepinephrine (Sigma-Aldrich),
10% FBS (Sigma-Aldrich), 1% v/v penicillin streptomycin (Invitrogen by Thermo Fisher Scientific,
Monza, Italy) and 2 mM L-glutamine (Invitrogen). Cells were cultured at 37 ◦C in a humid atmosphere
of 5% CO2 and 95% air. Cells were plated onto gelatin/fibronectin-coated flasks at a density
of 10,000 cells/cm2. When cells reached 90% of confluency, culture medium was replaced and
supplemented for 90 min with 2.5 µM SAHA.
4.4. Western Blot Analysis
Cells were washed in PBS and harvested in protein extraction buffer (10 mM Tris-HCl pH 7.4,
150 mM NaCl, 1% Igepal CA630, 1% sodium deoxycholate, 0.1% SDS (Sodium Dodecyl Sulphate)
and 1% Glycerol supplemented with protease/phosphatase inhibitor mix (Roche Diagnostics S.p.A.,
Milan, Italy). Proteins were quantified by BCA protein kit (Thermo Fisher Scientific, Monza, Italy)
following manufacturer’s instructions. Then, 30 µg of protein extracts were separated by SDS-PAGE
on precast gradient (4–12%) gels (Invitrogen) using MOPS running buffer (Invitrogen) and transferred
onto nitrocellulose membranes (Bio-Rad, Segrate, Milan, Italy) in Transfer buffer (Life Technologies by
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Thermo Fisher Scientific) supplemented with 10% (v/v) methanol (Sigma-Aldrich, Milan, Italy). After
blocking in 5% BSA in PBS containing 0.05% Tween 20 (1 h at room temperature), membranes were
incubated overnight at 4 ◦C with primary antibodies: SERCA2 (1:1000, SantaCruz, Dallas, TX, USA,
sc-376235), Acetylated-tubulin (1:1000, Sigma-Aldrich # T7451), GAPDH (glyceraldehyde-3-phosphate
dehydrogenase, 1:2000, SantaCruz, Dallas, TX, USA, sc-32233), Pan-Ac-K (Acetylated-Lysine, 1:1000,
Cell Signaling, Danvers, MA, USA, #9441), Phospho-PLB (Ser16) (Phospho-Phospholamban (Ser16),
1:5000, Merck Millipore, Billerica, MA, USA, # 07-052) and PLB (Phospholamban, 1:8000, Abcam,
Hong Kong, China, #ab2865). Blots were washed three times in PBS-Tween buffer and then incubated
with appropriate horseradish peroxidase conjugated secondary antibody (SantaCruz) for 1 h at room
temperature. Detection was performed by enhanced chemiluminescence system (Supersignal West
Dura Extended Duration Substrate, Thermo Scientific). Results were quantified by Image Lab software
5.2.1 (BioRad, Segrate-Milan, Italy).
4.5. Immunoprecipitation
Co-immunoprecipitation experiments were performed using protein-Agarose accordingly to
the manufacturer’s protocol (Roche Diagnostics S.p.A., Milan, Italy). In particular, 1 mg of protein
extracts was co-immunoprecipitated with 10 µg of anti-SERCA2 antibody (SantaCruz, Dallas, TX,
USA). Negative controls were performed with the same amount of protein extract (derived from
rat cardiomyocytes) and were immunoprecipitated with the corresponding purified IgG antisera
(SantaCruz) in the absence of primary antibody. Immunoprecipitated samples were resolved by
SDS–PAGE, transferred onto nitrocellulose membrane (Bio-Rad, Segrate-Milan; Italy) and western
blots were performed as described in the Section 4.4.
4.6. Isolation of the Microsomal Fraction
Microsome isolation from rat cardiomyocytes and HL-1 cells was performed according to
Maruyama and MacLennan (1988) with minor modifications [69]. Specifically, cells were washed twice
with PBS and then homogenized with 30 strokes in a glass Dounce homogenizer in 10 mM Tris-HCl,
pH 7.5, 0.5 mM MgCl2. The homogenate was diluted with an equal volume of a solution of 10 mM
Tris-HCl, pH 7.5, 0.5 M sucrose, 300 mM KCl. The suspension was centrifuged at 10,000× g for 30 min
at 4 ◦C to pellet nuclei and mitochondria. The pellet was discarded and the supernatant was further
centrifuged at 100,000× g for 150 min at 4 ◦C to sediment the microsomal fraction. The pellet was
re-suspended in a solution containing 0.25 M sucrose and 10 mM MOPS. All solutions were enriched
in protease inhibitors (Roche). The microsome concentration was measured using the BCA protein kit
(Thermo Fisher Scientific) following the manufacturer’s instructions.
4.7. ATP/NADH Coupled Assay for Calcium ATPase Activity
The ATPase activity of the microsomal fraction isolated from HL-1 cells (25 µg/mL), was measured
by spectrophotometric determination of NADH oxidation coupled to an ATP regenerating system,
as previously described [70]. We used a Beckman DU 640 spectrophotometer adjusted at a wavelength
of 340 nm. The assay was performed at 37 ◦C in a final volume of 1 mL of a buffer containing 20 mM
histidine pH 7.2, 5 mM MgCl2, 0.5 mM EGTA, 100 mM KCl, 2 mM ATP, 0.5 mM phosphoenolpyruvate,
0.15 mM NADH, 1.4 units of pyruvate kinase/lactic dehydrogenase, in the presence of 2 µg/mL A23187
Ca2+-ionophore. ATPase activity was obtained subtracting the basal activity (measured in the presence
of EGTA without calcium added) from the maximal activity and was expressed as micromoles/min/mg
of protein. For investigating the calcium-dependence of ATPase activity, the concentration of free
calcium was varied from pCa8 to pCa5 using EGTA buffered solutions.
NADH coupled ATPase assay protocol was then adapted for use on a 96-well microplate
reader, according to the method described by Kiianitsa and coworkers [71]. We used the microplate
protocol to analyze the ATPase activity of the microsomal fraction isolated from adult rat ventricular
cardiomyocytes (5 µg/well) and from HEK293 cells (20 µg/well) expressing either Wild Type or
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mutated human SERCA2a (see Section 4.10). The absorbance change at 340 nm was monitored using
the EnVision (Perkin Elmer, Waltham, MA, USA) plate reader. The experiments were performed at
37 ◦C in a final volume of 200 µL at pCa5 [21] on the same buffer described above. Technical duplicates
were performed for each experiment.
4.8. Rat Cardiomyocyte Mechanics and Calcium Transients
CM mechanical properties were assessed by using the IonOptix fluorescence and contractility
systems (IonOptix, Milton, MA, USA). CMs were placed in a chamber mounted on the stage of an
inverted microscope (Nikon-Eclipse TE2000-U, Nikon Instruments, Florence, Italy) and superfused
(1 mL/min at 37 ◦C) with a Tyrode solution containing (in mM): 140 NaCl, 5.4 KCl, 1 MgCl2, 5 HEPES,
5.5 glucose, and 1 CaCl2 (pH 7.4, adjusted with NaOH). Only rod-shaped myocytes with clear edges
and average sarcomere length ≥1.7 µm were selected for the analysis. All the selected myocytes
did not show spontaneous contractions. The cells were field stimulated at a frequency of 0.5 Hz
by constant current pulses (2 ms in duration, and twice diastolic threshold in intensity) delivered
by platinum electrodes placed on opposite sides of the chamber, connected to a MyoPacer Field
Stimulator (IonOptix). The stimulated myocyte was displayed on a computer monitor using an
IonOptix MyoCam camera. Load-free contraction of myocytes was measured with the IonOptix
system, which captures sarcomere length dynamics via a Fast Fourier Transform algorithm. Sampling
rate was fixed at 1 KHz. A total of 115 control isolated ventricular myocytes (of which 45 were used as
untreated control and 70 were exposed to SAHA) were analyzed to compute the following parameters:
mean diastolic sarcomere length and fraction of shortening (FS), maximal rates of shortening and
re-lengthening (±dl/dtmax), and time at 10%, 50% and 90% of re-lengthening (RL10, RL50 and RL90,
respectively). Steady-state contraction of myocytes was achieved before data recording by means of a
10 s conditioning stimulation.
Calcium transients were measured simultaneously with cell motion. Ca2+ transients were detected
by epifluorescence after loading the myocytes with Fluo-3 AM (10 µmol/L; Invitrogen, Carlsbad, CA,
USA) for 30 min. Excitation length was 480 nm, with emission collected at 535 nm using a 40× oil
objective lens (NA: 1.3). Fluo-3 signals were expressed as normalized fluorescence (f/f0: fold increase).
The time course of the fluorescence signal decay was described by a single exponential equation,
and the time constant (tau) was used as a measure of the rate of intracellular calcium clearing [72].
The time to peak of the calcium transients (TTP) and the times to 10%, 50% and 90% of fluorescence
signal decay were also measured (time to BaseLine fluorescence BL10, BL50 and BL90, respectively).
4.9. Bioinformatics Analysis
The post-translation modification databases PHOSIDA [73] and PhosphoSitePlus [74] were
used for the identification of acetylation sites investigated in human SERCA2. The location of the
lysine acetylation was investigated in human SERCA2a structural models derived by homology
modelling based on rabbit homologue templates with 83% sequence identity to hSERCA2a, and using
MODELLER version 9.11 [75].
4.10. Mutagenesis
SERCA2a mutants were generated by PCR-site directed mutagenesis (for a list of primers see Table
S1) and verified by complete sequencing (Eurofins Genomics, Ebersberg, Germany). The SERCA2a
wild-type coding sequence (NM_001681.3; SER-WT) as well as the SERCA2a coding sequence with
Lys 464 residue mutated into glutamine (SER-K464Q) or arginine (SER-K464R) were subsequently
cloned into the pCDNA3 vector carrying Geneticin resistance (Life Technologies) for subsequent cell
transfection. Transfections were performed on HEK-MSR1 cells (Human Embryonic Kidney 293 cells)
that stably express human Macrophage Scavenger Receptor 1, facilitating cell adhesion in blasticidin
selection (5 µg/mL, Invitrogen) [76]. Lipofectamine LTX (Invitrogen) was used for transfection
following manufacturer’s instructions. Stable cell lines were selected 24 h after transfections in culture
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medium composed by: MEM (Invitrogen) supplemented with 10% FBS (Sigma-Aldrich), 1% v/v
glutamine (Invitrogen), 1% v/v minimum non-essential amino acids (Invitrogen) and 450 µg/mL
Geneticin (Invitrogen).
4.10.1. SERCA2 Mutant Calcium Transients
HEK-MSR1 stably transfected with K464 onto SERCA2 sequence mutated in Q or R were plated
on the bottom of glass dishes (25 mm diameter) and grown for 2 days in MEM medium supplemented
with FBS 10%. Cytosolic Ca2+ dynamics were evaluated in Fluo-4 AM loaded cells. Briefly, cells were
loaded with 2.5 µM of Fluo-4 AM (Molecular Probes, Invitrogen) for 30 min at 37 ◦C and then
washed with Tyrode’s solution containing in mM: 10 D-(+)-glucose, 5.0 Hepes, 140 NaCl, 5.4 KCl,
1.2 MgCl2, 1.8 CaCl2, pH adjusted to 7.3 with NaOH. Dishes were mounted in a perfusion chamber
and placed on the stage of an epifluorescence microscope (Nikon) equipped with a 75 W Xenon
lamp and connected to a CCD camera (Cool SnapTM EZ Photometrics, Tucson, AZ, USA). Cells were
excited at 488 nm wavelength, fluorescence emission was measured at 520 nm and recorded using the
MetaFluor Software (Molecular Devices, Sunnyvale, CA, USA); imaging was scanned repeatedly at
20 Hz. This low temporal acquisition is justified by the longer calcium transient in HEK cells lasting on
average 1 min and 20 s. Calcium transients were evoked by a 1 s caffeine-pulse (10 mM). Temperature
was maintained at 36.5 ± 0.5 ◦C throughout the experiment.
The background fluorescence signal was fitted to a linear regression and then subtracted.
Each trace was subsequently resampled and denoised with an Rbf interpolator (f = 20, e = 1, s = 1).
The baseline was calculated per-trace using the median value of the first 250 ms before the excitation
and then subtracted.
Traces which didn’t reach a peak value of at least 2 times the baseline level, or dropped under
90% of the absolute value of the baseline were discarded. We then calculated the time to decay at
the first intersection of 10%, 50% and 90% of the curves, thus defining time to BL10, BL50 and BL90.
Only traces that successfully recovered to BL90 within the recording timeline (90 s) were considered.
4.10.2. Statistical Analysis
All data are reported as means ± standard error (SEM). Normality of the data was evaluated
by D’Agostino & Pearson normality test. For two groups, significance was assessed by two-tailed
unpaired t-test or non-parametric Mann–Whitney U-test when appropriate. For more than two groups
either two-way ANOVA, parametric one-way ANOVA or Kruskal-Wallis non parametric test were used
followed by appropriate post-hoc individual comparisons (GraphPad Prism software 6.03). General
Linear Model (GLM) ANOVA for repeated measurements was used to compare cell contractility and
calcium transient data (IBM-SPSS 24.0, SPSS Inc., Chicago, IL, USA). The details on the specific test
used are reported in the figure legend of each specific experiment. A p-value < 0.05 was considered
statistically significant.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/2079-6382/19/2/419/s1.
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